About: Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
Creator	Fischer, Stefanie Larkin, James Porta, Camillo Rini, Brian Gruenwald, Viktor Aeppli, Stefanie Eboulet, Eric Eisen, Tim Escudier, Bernard Mcdermott, David Oldenburg, Jan Omlin, Aurelius Rothermundt, Christian Schmidinger, Manuela Sternberg, Cora
Source	Medline; PMC
abstract	BACKGROUND: The coronavirus pandemic has provoked discussions among healthcare providers how to manage cancer patients when faced with the threat of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) infection. Immune checkpoint inhibitor (ICI) containing regimens are standard of care in the majority of metastatic clear cell renal cell carcinoma (mccRCC) patients. It remains unclear whether therapies should be modified in response to the COVID-19 pandemic. METHODS: We performed an online survey among physicians involved in the treatment of mccRCC, and 41 experts responded. Questions focused on criteria relevant for treatment decision outside the pandemic and the modifications of systemic therapy during COVID-19. FINDINGS: For the majority of experts (73%), the combination of International metastatic renal cell carcinoma Database Consortium (IMDC) risk category and patient fitness are two important factors for decision-making. The main treatment choice in fit, favourable risk patients outside the pandemic is pembrolizumab/axitinib for 53%, avelumab/axitinib, sunitinib or pazopanib for 13% of experts each. During the pandemic, ICI-containing regimens are chosen less often in favour of a tyrosine kinase inhibitors (TKI) monotherapy, mainly sunitinib or pazopanib (35%). In fit, intermediate/poor-risk patients outside the pandemic, over 80% of experts choose ipilimumab/nivolumab, in contrast to only 41% of physicians during COVID-19, instead more TKI monotherapies are given. In patients responding to established therapies with ICI/ICI or ICI/TKI combinations, most participants modify treatment regimen by extending cycle length, holding one ICI or even both. CONCLUSION: mccRCC treatment modifications in light of the coronavirus pandemic are variable, with a shift from ICI/ICI to ICI/TKI or TKI monotherapy.
has issue date	2020-07-14(xsd:dateTime)
bibo:doi	10.1136/esmoopen-2020-000852
bibo:pmid	32669298
has license	no-cc
sha1sum (hex)	8459a12e4a7336747294861078161e896710dad4
schema:url	https://doi.org/10.1136/esmoopen-2020-000852
resource representing a document's title	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
has PubMed Central identifier	PMC7368485
has PubMed identifier	32669298
schema:publication	ESMO Open
resource representing a document's body	covid:8459a12e4a7336747294861078161e896710dad4#body_text
is schema:about of	named entity 'responded' named entity 'During' named entity 'therapies' named entity 'focused' named entity 'COVID-19' named entity 'choice' named entity 'therapies' named entity 'pazopanib' named entity 'COVID-19' named entity 'clear cell renal cell carcinoma' named entity 'TREATMENT REGIMEN' named entity 'PEMBROLIZUMAB' named entity 'PARTICIPANTS' named entity 'MAJORITY' named entity 'CONSORTIUM' named entity 'LIGHT' named entity 'ON TREATMENT' named entity 'checkpoint inhibitor' named entity 'provoked' named entity 'ICI' named entity 'ICI' named entity 'response' named entity 'intermediate' named entity 'nivolumab' named entity 'ICI' named entity 'combinations' named entity 'severe acute respiratory syndrome' named entity 'experts' named entity 'pandemic' named entity 'patterns' named entity 'standard of care' named entity 'sunitinib' named entity 'metastatic' named entity 'ICI' named entity 'tyrosine kinase inhibitors' named entity 'ipilimumab' named entity 'infection' named entity 'ICI' named entity 'ICI' named entity 'Immune checkpoint inhibitor' named entity 'coronavirus 2' named entity 'COVID-19' named entity 'pembrolizumab' named entity 'systemic therapy' named entity 'physical distancing' named entity 'pembrolizumab' named entity 'ipilimumab' named entity 'ICI' named entity 'SARS-CoV-2' named entity 'ICI' named entity 'ipilimumab' named entity 'axitinib' named entity 'sunitinib' named entity 'tumour' named entity 'ICI' named entity 'targeted therapy' named entity 'clear cell renal cell carcinoma' named entity 'asymptomatic' named entity 'infection' named entity 'ICI' named entity 'monotherapy' named entity 'ipilimumab' named entity 'TKI' named entity 'axitinib' named entity 'PD-L1' named entity 'systemic therapy' named entity 'hazard ratio'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software